RT Journal Article
SR Electronic
T1 Urinary metabolic biomarkers of diet quality in European children are associated with metabolic health
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.09.21263335
DO 10.1101/2021.09.09.21263335
A1 Nikolaos Stratakis
A1 Alexandros P. Siskos
A1 Eleni Papadopoulou
A1 Anh N. Nguyen
A1 Yinqi Zhao
A1 Katerina Margetaki
A1 Chung-Ho E. Lau
A1 Muireann Coen
A1 Lea Maitre
A1 Silvia Fernández-Barrés
A1 Lydiane Agier
A1 Sandra Andrusaityte
A1 Xavier Basagaña
A1 Anne Lise Brantsaeter
A1 Maribel Casas
A1 Serena Fossati
A1 Regina Grazuleviciene
A1 Barbara Heude
A1 Rosemary R C McEachan
A1 Helle Margrete Meltzer
A1 Christopher Millett
A1 Fernanda Rauber
A1 Oliver Robinson
A1 Theano Roumeliotaki
A1 Eva Borràs
A1 Eduard Sabidó
A1 Jose Urquiza
A1 Marina Vafeiadi
A1 Paolo Vineis
A1 Trudy Voortman
A1 John Wright
A1 David V. Conti
A1 Martine Vrijheid
A1 Hector C. Keun
A1 Leda Chatzi
YR 2021
UL http://medrxiv.org/content/early/2021/09/14/2021.09.09.21263335.abstract
AB Urinary metabolic profiling is a promising powerful tool to reflect dietary intake and can help understand metabolic alterations in response to diet quality. Here, we used 1H-NMR spectroscopy in a multi-country study in European children (1147 children from 6 different cohorts) and identified a common panel of 4 urinary metabolites (hippurate, N-methylnicotinic acid, urea and sucrose) that was predictive of Mediterranean diet adherence (KIDMED) and ultra-processed food (UPF) consumption and also had higher capacity in discriminating children’s diet quality than that of established sociodemographic determinants. Further, we showed that the identified metabolite panel also reflected the associations of these diet quality indicators with C-peptide, a stable and accurate marker of insulin resistance and future risk of metabolic disease. This methodology enables objective assessment of dietary patterns in European child populations, complementary to traditional questionary methods, and can be used in future studies to evaluate diet quality. Moreover, this knowledge can provide mechanistic evidence of common biological pathways that characterize healthy and unhealthy dietary patterns, and diet-related molecular alterations that could associate to metabolic disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no 308333 - the HELIX project. The STOP project (http://www.stopchildobesity.eu/) received funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement No. 774548. The STOP Consortium is coordinated by Imperial College London and includes 24 organisations across Europe, the United States and New Zealand. The content of this publication reflects only the views of the authors, and the European Commission is not liable for any use that may be made of the information it contains. INMA data collections were supported by grants from the Instituto de Salud Carlos III, CIBERESP, and the Generalitat de Catalunya-CIRIT. KANC was funded by the grant of the Lithuanian Agency for Science Innovation and Technology (6-04-2014_31V-66). For a full list of funding that supported the EDEN cohort, refer to: Heude B et al. Cohort Profile: The EDEN mother-child cohort on the prenatal and early postnatal determinants of child health and development. Int J Epidemiol. 2016 Apr;45(2):353-63. The Norwegian Mother, Father and Child Cohort Study (MoBa) is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. The Rhea project was financially supported by European projects, and the Greek Ministry of Health (Program of Prevention of Obesity and Neurodevelopmental Disorders in Preschool Children, in Heraklion district, Crete, Greece: 2011-2014; 'Rhea Plus': Primary Prevention Program of Environmental Risk Factors for Reproductive Health, and Child Health: 2012-2015). Born in Bradford received funding from the Wellcome Trust (101597). Professor Wright and McEachan receive funding from the National Institute for Health Research Applied Research Collaboration for Yorkshire and Humber. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. Dr. Maribel Casas received funding from Instituto de Salud Carlos III (Ministry of Economy and Competitiveness) (MS16/00128). Dr. Leda Chatzi was supported by NIH/NIHES R01 ES029944, R01ES030691, R01ES030364, R21 ES029681, R21 ES028903, and P30 ES007048-23. Dr. David Conti was supported by P01CA196569, R01CA140561, R01 ES016813, R01 ES029944, R01ES030691, R01ES030364. Dr. Nikos Stratakis was supported by NIH/NIHES R21 ES029681 and P30 ES007048-23, and NIH/NIDDK P30 DK048522-24. Dr. Hector Keun & Dr. Alexandros Siskos were also supported by the European Union's Horizon 2020 research and innovation programme under grant agreement No 874583 ("ATHLETE"). Dr. Eleni Papadopoulou was supported by the Research Council of Norway, under the MILJØFORSK program (project number: 268465). Dr. Fernanda Rauber was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo 2016/14302-7 and 2018/19820-1. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I+D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. ISGlobal acknowledges support from the Spanish Ministry of Science, Innovation and Universities, "Centro de Excelencia Severo Ochoa 2013-2017", SEV-2012-0208, and "Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat de Catalunya" (2017SGR595).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Southern California Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThe HELIX data warehouse has been established as an accessible resource for collaborative research involving researchers external to the project. Access to HELIX data is based on approval by the HELIX Project Executive Committee and by the individual cohorts. Further details on the content of the data warehouse (data catalog) and procedures for external access are described on the project website (http://www.projecthelix.eu/index.php/es/data-inventory).